Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Jefferies London Healthcare Conference 2023
15 slides from Vitrolife Ab's conference presentation, November 2023
Slide 1: Vitrolife Group - Excellence in Reproductive Health
Slide 2: Vitrolife AB (publ)
Vitrolife AB (publ) Bronwyn Brophy O´Connor, CEO Patrik Tolf, CFO Jefferies London Healthcare Conference November 2023
Slide 3: Introduction to Bronwyn Brophy
Introduction to Bronwyn Brophy Appointed CEO of Vitrolife AB on August 1st 26 years working in the Medtech and life sciences industries Former Vice Chair of Medtech Europe serving on the Operations Management Committee
Slide 4: Reproductive health market at a glance
Reproductive health market at a glance 1 in 6 people Cycle growth globally is 5-7%** affected by annually infertility* 140 million babies born annually, < 1% via IVF 4 *Source: World Health Organization (WHO) **Estimated cycle growth
Slide 5: Key market dynamics
Key market dynamics Growth in demand Labor and skills shortage Consolidation of clinics Regionalisation of standards of care Patient empowerment 5
Slide 6: Global presence
Global presence 125 ~1,100 Vitrolife AB (publ) listed on NASDAQ in markets employees Stockholm Large Cap 6
Slide 7: Well balanced global company
Well balanced global company Net sales of 2,607 MSEK (Jan-Sep 2023 ) by geographical segment and business area Direct presence in Consumables all major markets APAC Genetic 45% 31% Americas 33% Services 38% Revenue by Revenue by business geography area Serving 75% of EMEA Technologies fertility clin
Slide 8: Portfolio covering every step of the IVF journey
Portfolio covering Broad portfolio of every steptests products, of the IVFservices and journey IVF process Prenatal Pretreatment & Postnatal 8
Slide 9: 2023 YTD: Profitable growth and strong cash flow generation
2023 YTD: Profitable growth and strong cash flow generation Sales Organic growth* Gross margin 2,607 MSEK +5% 56.1% (2,379 MSEK) +10% in SEK In local currencies (55.3%) EBITDA adjusted for non-recurring costs Earnings per share Operating cash flow 868 MSEK 2.42 SEK 586 MSEK Margin 33.3% (32.6%) (2.3
Slide 10: Very robust performance in APAC
Very robust performance in APAC 2023 YTD Americas EMEA APAC Total Organic growth* -3% +6% +15% +5% Sales (MSEK) 869 943 795 2,607 Share of total sales 33% 36% 31% * Organic growth excluding discontinued business (Covid testing and GPDx China) 10
Slide 11: Why the Vitrolife Group is best placed to win profitably and sustainably
Why the Vitrolife Group is best placed to win profitably and sustainably EmbryoScope® Strong Focus on Best-in-class core to Innovative geographic operational portfolio automation/ pipeline presence excellence workflow 11
Slide 12: Capital Markets Day Stockholm 12th of December
Capital Markets Day Stockholm 12th of December
Slide 13: Thank you!
Thank you! Contact: Patrik Tolf, CFO, ptolf@vitrolife.com, +46 31 766 90 21 investors@vitrolife.com
Slide 14: VITROLIFE GROUP™
VITROLIFE GROUP™
Slide 15: Disclaimer
DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i
Vitrolife Group — Jefferies London Healthcare Conference 2023 on 6ix